Endobronchial Ultrasound Biopsy Market to Reach $1.28 Billion by 2033

According to Renub Research Latest Report endobronchial ultrasound (EBUS) biopsy market is witnessing steady growth, expected to expand from USD 820 million in 2024 to USD 1,275.36 million by 2033, at a CAGR of 5.03% between 2025 and 2033. The increasing prevalence of lung cancer and other pulmonary diseases, coupled with advancements in minimally invasive diagnostic technologies, is driving the demand for EBUS-guided biopsy procedures.

EBUS-guided biopsy is a less invasive alternative to conventional surgical biopsies, offering high precision in sampling lymph nodes and lung lesions. It is particularly crucial for diagnosing non-small cell lung cancer (NSCLC) and other thoracic malignancies, especially in peripheral or hard-to-reach areas. Its safety profile, faster recovery times, and real-time imaging capabilities have made it the preferred diagnostic method in modern pulmonary care.

Major players like Cook Medical, Boston Scientific, Medtronic, and Olympus Corporation are continuously innovating and conducting clinical research to improve EBUS technology and meet the growing demand worldwide.

Market Overview

The expansion of the EBUS biopsy market is fueled by several converging trends: the rising incidence of lung cancer, increasing prevalence of chronic respiratory diseases such as COPD and tuberculosis, aging populations, and a growing preference for minimally invasive diagnostic procedures.

According to the World Health Organization (WHO), the global population aged 60 and above is expected to reach 1.4 billion by 2030, up from 1.1 billion in 2021, driving the need for advanced diagnostic technologies like EBUS. Moreover, lung cancer continues to be a leading cause of cancer-related deaths globally, with risk factors including smoking, air pollution, and occupational hazards contributing to rising incidence rates.

In the United States alone, the American Cancer Society projects 226,650 new lung cancer cases in 2025, with an estimated 124,730 fatalities. Early and accurate detection is critical, and EBUS-guided biopsy plays a key role in improving patient outcomes by enabling precise staging and diagnosis.

👉 Want to explore detailed market trends, segment insights, and forecasts? 🔗 Request Free Sample Report

Key Market Drivers

1. Rising Incidence of Lung Cancer

Lung cancer, particularly NSCLC, remains one of the most fatal cancers worldwide. Early detection and accurate staging are critical for improving treatment outcomes. EBUS-guided biopsies allow clinicians to sample lymph nodes and lung lesions with high precision while minimizing invasiveness.

As the prevalence of lung cancer rises globally, healthcare providers increasingly rely on EBUS to integrate less invasive procedures into standard diagnostic pathways, boosting market demand.

2. Shift Toward Minimally Invasive Procedures

There is a significant trend in healthcare toward minimally invasive techniques, especially for diagnosing cancer. Traditional surgical biopsies often involve long hospital stays, higher risk, and extended recovery times.

EBUS offers real-time imaging guidance, enabling precise tissue sampling with reduced patient discomfort and complications. Faster recovery and lower healthcare costs make EBUS an attractive alternative, further propelling market growth.

3. Adoption in Emerging Markets

Emerging regions, including India, Saudi Arabia, and parts of Asia-Pacific, are experiencing increased adoption of EBUS due to expanding healthcare infrastructure, rising awareness of lung cancer, and government initiatives to improve healthcare access.

Hospitals and specialty clinics are increasingly equipped with advanced EBUS systems, allowing for early diagnosis and staging of pulmonary diseases. Awareness campaigns highlighting the advantages of minimally invasive procedures further drive demand in these regions.

Market Challenges

1. High Equipment Costs

One of the major barriers to widespread adoption of EBUS is the high cost of equipment. EBUS systems require a substantial upfront investment, including specialized scopes, needles, imaging systems, and ongoing maintenance.

Smaller hospitals or clinics with budget constraints may find it challenging to justify this expenditure. Additionally, ongoing staff training and equipment calibration contribute to the total cost, limiting adoption in low-resource settings.

2. Limited Availability of Trained Personnel

Effective EBUS procedures depend on skilled pulmonologists and technicians proficient in operating the equipment and interpreting imaging results.

A shortage of trained personnel, especially in rural areas and developing countries, can hinder the adoption of EBUS technology. Operator skill directly impacts diagnostic accuracy, and a lack of expertise may delay procedures, compromise results, and slow market growth.

Regional Market Insights

United States

The U.S. EBUS biopsy market is expanding rapidly due to the high prevalence of lung cancer and the adoption of minimally invasive diagnostic methods. EBUS allows clinicians to access hard-to-reach lesions and stage diseases accurately.

Advanced healthcare infrastructure, ongoing technological innovations, and a strong regulatory framework position the U.S. as a global leader in the EBUS biopsy market. According to the ACS Cancer Statistics 2024, approximately 234,500 lung and bronchus cancer cases are expected in 2024 alone, highlighting the urgent need for precise, minimally invasive diagnostics.

United Kingdom

The UK market is growing steadily due to increased lung disease prevalence, the adoption of minimally invasive techniques, and strong support from the national healthcare system.

Government-backed programs and comprehensive reimbursement policies facilitate EBUS adoption. However, high equipment costs and the need for specialized training may limit rapid deployment in smaller hospitals or clinics.

India

India’s market is witnessing significant growth due to rising lung disease prevalence and expanding healthcare infrastructure. Hospitals and specialty clinics are increasingly incorporating EBUS systems for accurate diagnosis and staging of pulmonary diseases.

Government initiatives promoting advanced diagnostic technologies and improving healthcare accessibility support the adoption of EBUS, although cost and training barriers remain challenges for widespread implementation.

Saudi Arabia

The EBUS market in Saudi Arabia is expanding alongside growing investments in healthcare infrastructure and awareness of minimally invasive diagnostics. Hospitals and specialty clinics increasingly employ EBUS for accurate staging of lung cancer and other respiratory diseases, aided by government programs aimed at improving healthcare access and quality.

Recent Developments in the Industry

GE Healthcare (October 2024): Expanded production of medical imaging devices, including MRI and ultrasound systems, in Waukesha County, Wisconsin, to meet growing global demand.

FUJIFILM Healthcare Europe GmbH (September 2024): Launched the ARIETTA 750 FF ENDO ultrasound system, compatible with linear bronchoscopes and multiple ultrasound endoscopes. Features include Carving Imaging for better visualization and eFocusing for sharper images.

Praxis EndoCore (October 2023): Received FDA approval for EndoCore EBUS-TBNA biopsy equipment, designed to enhance the precision and effectiveness of lung biopsies, improving tissue sampling and patient outcomes.

👉 For deeper analysis, detailed segment data, and company insights: 🔗 Request Customization Report

Market Segmentation

By Product

EBUS Scopes

EBUS Needles

Ultrasound Processors and Imaging Systems

Accessories

By Application

Cancer Diagnostics

Infection Diagnostics

Others

By End Use

Hospitals

Ambulatory Surgical Centers (ASCs)

Specialty Clinics

By Region

North America: U.S., Canada

Europe: U.K., Germany, France, Italy, Spain, Belgium, Netherlands, Turkey

Asia-Pacific: China, India, Japan, Australia, South Korea, Thailand, Malaysia, Indonesia, New Zealand

Latin America: Brazil, Mexico, Argentina

Middle East & Africa: Saudi Arabia, UAE, South Africa

Competitive Landscape

The EBUS biopsy market is highly competitive, with major players focusing on product innovation, clinical research, and geographic expansion. Key companies include:

GE Healthcare – Advanced ultrasound and imaging solutions.

Siemens Healthcare – Cutting-edge imaging systems for minimally invasive diagnostics.

Koninklijke Philips N.V. – Innovative diagnostic equipment with enhanced imaging capabilities.

Boston Scientific Corporation – Specialized EBUS scopes and needles for pulmonary procedures.

Olympus Corporation – Leader in endoscopic and minimally invasive technologies.

Cook Group Incorporated – EBUS needles and accessories.

FUJIFILM Holdings Corporation – Advanced ultrasound systems and EBUS solutions.

Medi-Globe Technologies GmbH – Precision instruments for EBUS-guided biopsies.

These companies compete through technological upgrades, enhanced imaging capabilities, and global market expansion, focusing on both developed and emerging regions.

Market Outlook

The global endobronchial ultrasound biopsy market is expected to grow steadily due to:

Increasing lung cancer prevalence and need for accurate staging.

Rising demand for minimally invasive diagnostic procedures with faster recovery and reduced complications.

Expansion of healthcare infrastructure and advanced medical technologies in emerging markets.

Continued innovation in imaging systems, biopsy instruments, and procedural efficiency.

Growing awareness among clinicians and patients regarding the advantages of EBUS over traditional surgical biopsies.

By 2033, the market is projected to reach USD 1.28 billion, with hospitals and specialty clinics leading adoption due to their ability to invest in advanced equipment and trained personnel. EBUS technology will continue to reshape pulmonary diagnostics, offering precise, minimally invasive solutions for lung cancer and other respiratory diseases.

With technological innovation, expanding healthcare infrastructure, and rising disease prevalence, the EBUS biopsy market is poised for sustained growth in the next decade.

Note: If you need details, data, or insights not covered in this report, we are glad to assist. Through our customization service, we will collect and deliver the information you require, tailored to your specific needs. Share your requirements with us, and we will update the report to align with your expectations.